Indication
Chronic Myelogenous Leukemia (CML)
5 clinical trials
8 products
1 drug
Product
NilotinibProduct
NiCordClinical trial
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological MalignanciesStatus: Active (not recruiting), Estimated PCD: 2021-04-29
Clinical trial
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)Status: Completed, Estimated PCD: 2022-09-19
Product
TacrolimusProduct
MethotrexateProduct
Mycophenolate MofetilDrug
cyclophosphamideClinical trial
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other IndicationsStatus: Recruiting, Estimated PCD: 2041-10-01
Clinical trial
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in AdultsStatus: Recruiting, Estimated PCD: 2028-05-22
Product
Conditioning ChemotherapyProduct
Cord blood graft